ATE369435T1 - Paramyxoviren, die eine modifizierte transkriptionsstartsequenz umfassen - Google Patents

Paramyxoviren, die eine modifizierte transkriptionsstartsequenz umfassen

Info

Publication number
ATE369435T1
ATE369435T1 AT00956962T AT00956962T ATE369435T1 AT E369435 T1 ATE369435 T1 AT E369435T1 AT 00956962 T AT00956962 T AT 00956962T AT 00956962 T AT00956962 T AT 00956962T AT E369435 T1 ATE369435 T1 AT E369435T1
Authority
AT
Austria
Prior art keywords
sequence
gene
vectors
expression
transcription
Prior art date
Application number
AT00956962T
Other languages
English (en)
Inventor
Yoshiyuki Nagai
Atsushi Kato
Mamoru Hasegawa
Original Assignee
Dnavec Research Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dnavec Research Inc filed Critical Dnavec Research Inc
Application granted granted Critical
Publication of ATE369435T1 publication Critical patent/ATE369435T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18811—Sendai virus
    • C12N2760/18822—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18811—Sendai virus
    • C12N2760/18841—Use of virus, viral particle or viral elements as a vector
    • C12N2760/18843—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Bakery Products And Manufacturing Methods Therefor (AREA)
AT00956962T 1999-09-06 2000-09-06 Paramyxoviren, die eine modifizierte transkriptionsstartsequenz umfassen ATE369435T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP25223199 1999-09-06

Publications (1)

Publication Number Publication Date
ATE369435T1 true ATE369435T1 (de) 2007-08-15

Family

ID=17234351

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00956962T ATE369435T1 (de) 1999-09-06 2000-09-06 Paramyxoviren, die eine modifizierte transkriptionsstartsequenz umfassen

Country Status (13)

Country Link
US (1) US7144579B2 (de)
EP (1) EP1211318B1 (de)
JP (1) JP3748535B2 (de)
KR (1) KR100776086B1 (de)
CN (1) CN1367839A (de)
AT (1) ATE369435T1 (de)
AU (1) AU6872000A (de)
CA (1) CA2376106A1 (de)
DE (1) DE60035885T2 (de)
DK (1) DK1211318T3 (de)
ES (1) ES2288866T3 (de)
HK (1) HK1047450A1 (de)
WO (1) WO2001018223A1 (de)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6490775B1 (en) * 1999-04-23 2002-12-10 Veri-Tek Inc. Press operation verification system
US7226786B2 (en) * 1999-05-18 2007-06-05 Dnavec Research Inc. Envelope gene-deficient Paramyxovirus vector
US20030166252A1 (en) * 1999-05-18 2003-09-04 Kaio Kitazato Paramyxovirus-derived RNP
US7314614B1 (en) 1999-11-02 2008-01-01 Dnavec Research, Inc. Recombinant sendai virus vector for introducing exogenous genes to airway epithelia
CN1418252A (zh) * 2000-01-19 2003-05-14 株式会社载体研究所 副粘病毒属载体在血管内基因转移中的用途
WO2001072340A1 (fr) 2000-03-30 2001-10-04 Dnavec Research Inc. Vaccin contre le virus du sida, contenant un vecteur du virus de sendai
KR100807016B1 (ko) * 2000-06-01 2008-02-25 가부시키가이샤 디나벡크 겐큐쇼 헤마글루티닌 활성을 갖는 막단백질을 포함하는 슈도타입레트로바이러스 벡터
KR20030014392A (ko) * 2000-06-27 2003-02-17 가부시키가이샤 디나벡크 겐큐쇼 신장세포에 유전자를 도입하기 위한 바이러스 벡터
CA2424992A1 (en) * 2000-10-06 2003-04-04 Dnavec Research Inc. Paramyxovirus vectors for introducing foreign genes into skeletal muscle
JP2002142770A (ja) 2000-11-08 2002-05-21 Dnavec Research Inc 循環系への遺伝子送達用パラミクソウイルスベクター
WO2003029475A1 (en) * 2001-09-28 2003-04-10 Dnavec Research Inc. MAMMALIAN CELL-INFECTING VIRUS VECTOR ENCODING EPITOPE-BOUND β2m AND UTILIZATION THEREOF
JPWO2003092738A1 (ja) * 2002-04-30 2005-09-08 株式会社ディナベック研究所 ヘマグルチニン活性を低下させた薬剤または遺伝子運搬組成物
JPWO2004022731A1 (ja) * 2002-09-04 2005-12-22 株式会社ディナベック研究所 シアル酸結合活性を有する膜蛋白質をエンベロープに含むウイルスベクターをグラム陽性菌由来ノイラミニダーゼを用いて製造する方法
WO2004031380A1 (ja) * 2002-10-01 2004-04-15 Dnavec Research Inc. TAP活性の阻害により MHC class I による外来エピトープの提示を増強する方法
CA2503317A1 (en) * 2002-10-24 2004-05-06 Dnavec Research Inc. Method of transferring gene into t cells
CA2514937A1 (en) * 2003-01-31 2004-08-12 Dnavec Research Inc. Paramyxoviral vectors encoding ribozymes and uses thereof
US20070105208A1 (en) * 2003-06-30 2007-05-10 Jun You Minus strand rna virus vector carrying gene modified in high mutation region
EP1715048A4 (de) * 2004-01-22 2007-02-07 Dnavec Research Inc Verfahren zur herstellung eines virusvektors
AU2005206410A1 (en) 2004-01-22 2005-08-04 Dnavec Research Inc. Method of producing minus strand RNA virus vector with the use of hybrid promoter containing cytomegalovirus enhancer and avian beta-actin promoter
KR20080016955A (ko) 2005-06-14 2008-02-22 디나벡크 가부시키가이샤 항체의 제작방법
EP2993235B1 (de) 2005-10-28 2019-02-13 ID Pharma Co., Ltd. Gentransfer in epithelialen stammzellen der atemwege unter verwendung von similian lentiviralen vektoren mit senadai rna-virus-spikeprotein pseudotypisierten vektoren
CA2636600A1 (en) 2006-01-17 2007-07-26 Dnavec Corporation Novel protein expression system
WO2007139178A1 (ja) 2006-05-31 2007-12-06 Dnavec Corporation アルツハイマー病治療薬
US20100323428A1 (en) 2007-02-07 2010-12-23 Dnavec Corporation Attenuated minus-stranded rna virus
WO2008129971A1 (ja) * 2007-04-13 2008-10-30 National Institute Of Advanced Industrial Science And Technology 改良された持続感染型センダイウイルスベクター
US20100203027A1 (en) 2007-04-27 2010-08-12 Kyushu Univeristy National University Viral vector for gene therapy
CA2731007A1 (en) 2008-07-16 2010-01-21 Dnavec Corporation Method for production of reprogrammed cell using chromosomally unintegrated virus vector
CN102272302B (zh) 2008-10-31 2015-04-15 生物载体株式会社 增强重组蛋白表达的方法
CN102711812B (zh) 2010-01-08 2014-07-16 国立大学法人京都大学 Tau蛋白病治疗用疫苗
EP2612911B1 (de) 2010-08-30 2018-01-17 ID Pharma Co., Ltd. Zusammensetzung zur induktion pluripotenter stammzellen und ihre verwendung
CN105916980A (zh) 2013-09-24 2016-08-31 株式会社爱迪药业 用于改进诱导多能干细胞的效率的方法
CN110234347A (zh) 2016-11-17 2019-09-13 国立传染病研究所长代表日本国 使用了非感染性副粘病毒粒子的传染病疫苗
CN111479920A (zh) 2017-07-21 2020-07-31 株式会社爱医隆集团 用于修饰靶序列的多核苷酸及其用途
EP3744847A4 (de) 2018-01-22 2021-12-08 Japan as Represented by The Director-General of National Institute of Infectious Diseases Selektives cd8-positives t-zellinduzierendes impfstoffantigen
CN111733170A (zh) * 2020-07-01 2020-10-02 青岛农业大学 一种表达荧光素酶的重组犬麻疹病毒
US20230220025A1 (en) 2020-09-04 2023-07-13 Heartseed Inc. Quality Improving Agent for IPS Cells, Method of Producing IPS Cells, IPS Cells, and Composition for Producing IPS Cells
EP4269571A1 (de) 2020-12-25 2023-11-01 Kyoto University Verfahren zur herstellung von naiven menschlichen ips-zellen aus somatischen zellen

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE298789T1 (de) 1995-10-31 2005-07-15 Dnavec Research Inc Negativstrand rna virus mit selbständiger replikationsaktivität
CN1143892C (zh) 1995-11-01 2004-03-31 株式会社载体研究所 重组仙台病毒
KR100658491B1 (ko) * 1996-07-15 2006-12-18 더 가번먼트 오브 더 유나이티드 스테이츠 오브 아메리카, 에즈 레프리젠티드 바이 더 디파트먼트 오브 헬쓰 앤드 휴먼 서비시즈 클론닝된 뉴클레오타이드 서열로부터 약독화된 호흡기 세포 융합 바이러스 백신의 생산
US6828138B1 (en) 1998-08-11 2004-12-07 Dnavec Research Inc. Recombinant sendai virus vector including a gene encoding a chemokine
US20030166252A1 (en) 1999-05-18 2003-09-04 Kaio Kitazato Paramyxovirus-derived RNP
US7226786B2 (en) 1999-05-18 2007-06-05 Dnavec Research Inc. Envelope gene-deficient Paramyxovirus vector
CN1418252A (zh) 2000-01-19 2003-05-14 株式会社载体研究所 副粘病毒属载体在血管内基因转移中的用途
WO2001072340A1 (fr) 2000-03-30 2001-10-04 Dnavec Research Inc. Vaccin contre le virus du sida, contenant un vecteur du virus de sendai
CA2322057A1 (en) 2000-05-18 2001-11-18 Dnavec Research Inc. Paramyxovirus vectors used for transfer of foreign genes
KR100807016B1 (ko) 2000-06-01 2008-02-25 가부시키가이샤 디나벡크 겐큐쇼 헤마글루티닌 활성을 갖는 막단백질을 포함하는 슈도타입레트로바이러스 벡터
KR20030014392A (ko) 2000-06-27 2003-02-17 가부시키가이샤 디나벡크 겐큐쇼 신장세포에 유전자를 도입하기 위한 바이러스 벡터
CA2424992A1 (en) 2000-10-06 2003-04-04 Dnavec Research Inc. Paramyxovirus vectors for introducing foreign genes into skeletal muscle
JP2002142770A (ja) 2000-11-08 2002-05-21 Dnavec Research Inc 循環系への遺伝子送達用パラミクソウイルスベクター
AU2002224113A1 (en) 2000-11-27 2002-06-03 Dnavec Research Inc. Paramyxovirus vector encoding angiogenesis gene and utilization thereof

Also Published As

Publication number Publication date
DE60035885T2 (de) 2008-05-08
EP1211318A4 (de) 2003-08-13
US20040121308A1 (en) 2004-06-24
WO2001018223A1 (fr) 2001-03-15
DK1211318T3 (da) 2007-11-12
JP3748535B2 (ja) 2006-02-22
DE60035885D1 (de) 2007-09-20
EP1211318A1 (de) 2002-06-05
KR100776086B1 (ko) 2007-11-15
ES2288866T3 (es) 2008-02-01
HK1047450A1 (zh) 2003-02-21
KR20020013565A (ko) 2002-02-20
US7144579B2 (en) 2006-12-05
AU6872000A (en) 2001-04-10
EP1211318B1 (de) 2007-08-08
CN1367839A (zh) 2002-09-04
CA2376106A1 (en) 2001-03-15

Similar Documents

Publication Publication Date Title
ATE369435T1 (de) Paramyxoviren, die eine modifizierte transkriptionsstartsequenz umfassen
UA92132C2 (ru) Высокоактивные рекомбинантные вирусы гриппа для вакцин и генотерапии
HK1125674A1 (en) Rescue of influenza virus
ATE172642T1 (de) Impfstoffe und verfahren zu ihrer herstellung
EP3233113A1 (de) Ebolavirus- und marburgvirus-impfstoffe
NO20062948L (no) Promotere for ekspresjon i modifisert vaccinia-virus Ankara
IL188362A0 (en) Attenuated negative strand viruses with altered interferon antagonist activity for use as vaccines and pharmaceuticals
ATE437175T1 (de) Infektiöse cdna eines zugelassenen impfstammes des masern virus. verwendung in immunogenen zusammensetzungen
IL182512A0 (en) Method for producing recombinant viruses of the mononegavirales order
WO2006136448A3 (en) Attenuated sars and use as a vaccine
DE69524618D1 (de) Abgeschwächtes impf- und gentransferase-virus, verfahren zu dessen herstellung und arzneimittel, das es enthält
BRPI0504945A (pt) método para a produção de vìrus recombinante contendo sequências de nucleotìdeos codificantes do todo ou parte de proteìnas heterólogas, constructos de dna, vìrus recombinantes resultantes e composições vacinais contendo tais vìrus recombinantes para imunizar contra flavivirus e/ou outros patógenos
WO2003072725A3 (en) Recombinant negative strand virus rna expression systems and vaccines
DE60302848D1 (de) Expression von genen im modifizierten vaccinia virus ankara durch verwendung eines cowpox ati promoter
DE60325838D1 (de) Imidazoquinolinamine als adjuvantien für hiv dna vakzine
ATE489106T1 (de) Virusähnliche partikel, verfahren zur herstellung und immunogene zusammensetzungen
MX2019014819A (es) Plásmido para inserción simplificada de secuencias cortas de adn en un cistrón que codifica para una proteína de cápside potyviral y método de aplicación.
Leitner Immune-Activating Mechanisms of Replicase-Based DNA and RNA Vaccines and Their Role in Immune-Apoptosis

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1211318

Country of ref document: EP

REN Ceased due to non-payment of the annual fee